MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13045-024-01555-4

Медицинская библиотека · Journal of hematology & oncology · 2024

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.

Zanwar Saurabh, Sidana Surbhi, Shune Leyla, Puglianini Omar Castaneda, Pasvolsky Oren, Gonzalez Rebecca, Dima Danai, Afrough Aimaz, Kaur Gurbakhash, Davis James A, Herr Megan, Hashmi Hamza, Forsberg Peter, Sborov Douglas, Anderson Larry D, McGuirk Joseph P, Wagner Charlotte, Lieberman-Cribbin Alex, Rossi Adriana, Freeman Ciara L, Locke Frederick L, Richard Shambavi, Khouri Jack, Lin Yi, Patel Krina K, Kumar Shaji K, Hansen Doris K

Письмо в редакциюМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain incompletely characterized. We included patients with RRMM treated with ide-cel between May 2021 and April 2023 across 11 US academic institutions. Visceral or soft tissue lesions non-contiguous from bone was classified as EMD. Time-to-event analyses were performed from date of ide-cel infusion. Among 351 patients, 84 (24%) had EMD prior to infusion. The median follow-up from ide-cel infusion was 18.2 months (95% CI: 17-19.3). The day 90 overall response rates (ORR) were 52% vs. 82% for the EMD and non-EMD cohorts, respectively (p < 0.001). The median progression-free survival (PFS) was 5.3 months (95% CI: 4.1-6.9) for the EMD cohort vs. 11.1 months (95% CI: 9.2-12.6; p < 0.0001) for the non-EMD cohort. In a multivariable analysis, EMD was an independent predictor of inferior PFS [hazard ratio 1.5 (1.1-2.2), p = 0.02]. The median overall survival was 14.8 months [95% CI: 9-Not reached (NR)] vs. 26.9 months (26.3 vs. NR, p = 0.006) for the EMD and non-EMD cohorts, respectively. Extramedullary disease represents an independent predictor of inferior day 90 ORR and PFS among patients treated with ide-cel.

Для цитирования: Zanwar Saurabh, Sidana Surbhi, Shune Leyla, Puglianini Omar Castaneda, Pasvolsky Oren, Gonzalez Rebecca, Dima Danai, Afrough Aimaz, Kaur Gurbakhash, Davis James A, Herr Megan, Hashmi Hamza, Forsberg Peter, Sborov Douglas, Anderson Larry D, McGuirk Joseph P, Wagner Charlotte, Lieberman-Cribbin Alex, Rossi Adriana, Freeman Ciara L, Locke Frederick L, Richard Shambavi, Khouri Jack, Lin Yi, Patel Krina K, Kumar Shaji K, Hansen Doris K. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.. Journal of hematology & oncology. 2024. DOI: 10.1186/s13045-024-01555-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.